Haleon plc (NYSE:HLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Haleon plc (NYSE:HLN) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $10.95.

HLN has been the subject of several research reports. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th.

Haleon Trading Up 1.7 %

Shares of HLN opened at $9.85 on Wednesday. Haleon has a 52-week low of $7.89 and a 52-week high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm’s fifty day moving average is $9.53 and its two-hundred day moving average is $9.79. The stock has a market cap of $44.57 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28.

Hedge Funds Weigh In On Haleon

Several institutional investors and hedge funds have recently bought and sold shares of HLN. FMR LLC grew its position in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after acquiring an additional 5,768,117 shares during the period. Wellington Management Group LLP grew its position in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after acquiring an additional 3,046,841 shares during the period. Douglas Lane & Associates LLC increased its position in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after purchasing an additional 161,865 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Haleon during the 4th quarter worth about $42,193,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.